Klamkin Jonathan sold $501K of ALMU
Klamkin Jonathan (Chief Executive Officer) sold 20,000 shares of Aeluma, Inc. (ALMU) at an average of $25.03 ($22.19–$26.25, $0.50M total) across 5 trades on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction reduces the CEO's ownership and may be interpreted as a lack of confidence, prompting short‑term selling pressure.
Market read
Insider sell of $500K by the CEO is a modest but noteworthy event for traders monitoring ALMU.
What to watch
Potential upcoming corporate actions or financing needs not disclosed in the filing.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan sale by a CEO is publicly reported.
Ticker impact
CEO Jonathan Klamkin sold 20,000 shares for $500.7K via a 10b5-1 plan, reducing his stake to 2,403 shares.
likely pressure as the market prices in the insider sell
A $500K sale by the CEO is a material insider transaction, albeit modest in size, that often leads to short-term downside sentiment.
Market effects
Minimal impact on the broader sector; the sale is company‑specific.
Limited to U.S. investors tracking insider activity.
Low; no cross‑border implications.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals, so the stock may remain stable.
Key entities
- CompanyAeluma, Inc.
US‑listed biotech company (ticker ALMU).
- ExecutiveJonathan Klamkin
Chief Executive Officer of Aeluma.

